Sustained Clinical Efficacy and Long-term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT (P9-9.003)

Arjun Seth; Yessar Hussain; Ali Habib; Kristl Claeys; Gregory Sahagian; Elena Cortes-Vicente; Jeffery Guptill; Li Liu; Rosa Jimenez; Sirine Bougamra; Delphine Masschaele; Renato Mantegazza; Andreas Meisel; Shahram Attarian

doi:10.1212/wnl.0000000000216346

June 9, 2026Neurology

Sustained Clinical Efficacy and Long-term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT (P9-9.003)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the long-term efficacy and safety of efgartigimod in patients with generalized myasthenia gravis.
Phase 3b trial design
Participants received efgartigimod via intravenous administration
Dosing was administered every-other-week or every-third-week
Efgartigimod demonstrated sustained clinical efficacy over the treatment period
Safety profile showed good tolerability among participants
Long-term use was associated with a favorable outcome in managing symptoms of generalized myasthenia gravis

Implication

Investigates long-term efficacy and safety of efgartigimod in generalized myasthenia gravis, indicating beneficial outcomes.

Abstract

Part B of the Phase 3b ADAPT NXT study in generalized myasthenia gravis (gMG; NCT04980495) investigated the long-term efficacy, safety, and tolerability of efgartigimod in participants with gMG receiving every-other-week (Q2W) or every-third-week (Q3W) dosing.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seth et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf300faef96ed7f0559aa https://doi.org/10.1212/wnl.0000000000216346

View Full Paper

Ask AI

Bookmark

Share

Sustained Clinical Efficacy and Long-term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT (P9-9.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

Sustained Clinical Efficacy and Long-term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT (P9-9.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading